A group of researchers from the University of Texas Medical Branch have developed a promising new antiviral drug candidate that could potentially treat a broad spectrum of viral infections, including dengue, SARS-CoV-2, and Zika. The new drug candidate, called EP67, is a small molecule that has been shown to be effective in inhibiting the replication of several viruses in laboratory studies. EP67 works by blocking the activity of an enzyme called a helicase, which is essential for many viruses to replicate. The researchers believe EP67 could be an effective treatment for a wide range of viral infections, and could even potentially be used as a prophylactic against future pandemics. The researchers are now working to develop EP67 into an approved medication and are hopeful that it could become a new standard of care for viral infections.

Read Full Article Here

source: Phys.org